期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 42, 期 5, 页码 1093-1105出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-022-01277-7
关键词
Intravenous immunoglobulins; Common variable immunodeficiency disorders (CVID); Human monocytes; Monocytic myeloid-derived suppressor cells
类别
资金
- CRUE-CSIC
- Ministerio de Economia y Competitividad [SAF2017-83785-R]
- Fundacion La Marato/TV3 [201619.31]
- Red de Investigacion en Enfermedades Reumaticas (RIER) [RD16/0012/0007]
- European Regional Development Fund A way to achieve Europe (ERDF)
- Instituto de Salud Carlos III (ISCIII) [19/284-E]
- Formacion de Personal Investigador predoctoral fellowship from MINECO [PRE2018-083396]
Common variable immunodeficiency disorders (CVID) is a primary immune deficiency characterized by hypogammaglobulinemia and impaired antibody responses. Intravenous Immunoglobulin (IVIg), a preparation of highly purified poly-specific IgG, exerts immunoregulatory and anti-inflammatory actions on peripheral blood monocytes, leading to an acquisition of an anti-inflammatory gene profile and altered proportions of monocyte subsets. CD14+ MDSC-like cells may contribute to the immunoregulatory effects of IVIg in CVID and other inflammatory disorders.
Common variable immunodeficiency disorders (CVID), the most common primary immune deficiency, includes heterogeneous syndromes characterized by hypogammaglobulinemia and impaired antibody responses. CVID patients frequently suffer from recurrent infections and inflammatory conditions. Currently, immunoglobulin replacement therapy (IgRT) is the first-line treatment to prevent infections and aminorate immune alterations in CVID patients. Intravenous Immunoglobulin (IVIg), a preparation of highly purified poly-specific IgG, is used for treatment of immunodeficiencies as well as for autoimmune and inflammatory disorders, as IVIg exerts immunoregulatory and anti-inflammatory actions on innate and adaptive immune cells. To determine the mechanism of action of IVIg in CVID in vivo, we determined the effect of IVIg infusion on the transcriptome of peripheral blood mononuclear cells from CVID patients, and found that peripheral blood monocytes are primary targets of IVIg in vivo, and that IVIg triggers the acquisition of an anti-inflammatory gene profile in human monocytes. Moreover, IVIg altered the relative proportions of peripheral blood monocyte subsets and enhanced the proportion of CD14(+) cells with a transcriptional, phenotypic, and functional profile that resembles that of monocytic myeloid-derived suppressor cells (MDSC). Therefore, our results indicate that CD14 + MDSC-like cells might contribute to the immunoregulatory effects of IVIg in CVID and other inflammatory disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据